AAT deficiency eLearning

• Should Your Patient Be Tested
• Your Newly Diagnosed Patient
• Managing Your AAT Deficient Patient

You will need Macromedia Flash
Player to view this program

Alpha₁-antitrypsin (AAT) deficiency* – which can lead to hereditary emphysema – is a common, easily diagnosed, and effectively managed hereditary disease.

*Also known as Alpha-1, AAT Deficiency, AATD, A₁-PI deficiency, alpha-1 antiprotease deficiency, A1AD, or hereditary or genetic emphysema.

AAT deficiency is more common than cystic fibrosis, spina bifida, Hodgkin's lymphoma, testicular cancer, and cervical cancer. Yet only 5% of AAT deficient patients have been identified.¹  Why? In part because symptoms of hereditary emphysema are easily confounded with symptoms of non-hereditary emphysema.

This eLearning session presents a case of a patient with typical symptoms. You may well recognize one or more of your patients in her story. By the end of the case study, you will see the differentiating factors in her symptoms and history, the appropriate timing and testing for AAT, and the options for effective disease management.

ARALAST [Alpha₁-Proteinase Inhibitor (Human)] is indicated for chronic augmentation therapy in patients having congenital deficiency of A₁-PI with clinically evident emphysema. ARALAST is not indicated as therapy for lung disease patients in whom congenital A₁-PI deficiency has not been established.

Please review the Important Safety Information and the Full Prescribing Information

1. National Survey of Patients with Alpha-1 Antitrypsin Deficiency in the United States. Conducted for the Alpha-1 Association, the Alpha-1 Foundation, and AlphaNet. May 2003.